Table 2 Clinical characteristics

Time since diagnosis of sarcoidosis (years), mean (SD)

23.7 (12.1)

Time since confirmation of PH (years), mean (SD)

5.5 (3.8)

Method used to confirm PH, n (%)

Right heart catheterization

9 (82)

Echocardiogram only

2 (18)

Current treatment for SAPH^a, n (%)

Anticoagulants

2 (18)

Calcium channel blockers

1 (9)

Diuretics

4 (36)

Endothelin receptor antagonists

6 (55)

Phosphodiesterase type 5 inhibitors

5 (45)

Oxygen

4 (36)

Current treatment for sarcoidosis^a, n (%)

Adrenocorticotropin hormone analogue

1 (9)

Bronchodilators

2 (18)

Corticosteroids

8 (73)

Hydroxychloroquine

0

Immunosuppressants (azathioprine)

1 (9)

Monoclonal antibodies (rituximab)

1 (9)

History of oxygen use^b

8 (73)

WHO functional class, n (%)

II

6 (55)

III

5 (45)

FVC (%), mean (SD)

58.1 (15.7)

FEV1 (L), mean (SD)

1.0 (0.4)

Pulmonary arterial pressure (mmHg), mean (SD)

35.6 (5.4)

Comorbid conditions^a, n (%)

Anemia

2 (18)

Anxiety

4 (36)

Asthma

4 (36)

Atrial fibrillation

4 (36)

Congestive heart failure

2 (18)

Degenerative disk disease

2 (18)

Depression

3 (27)

Diabetes

3 (27)

 With chronic complications

1 (9)

 Without chronic complications

2 (18)

Gastroesophageal reflux disease

1 (9)

Hypertension

6 (55)

Hypersensitivity lung disease

2 (18)

Obstructive sleep apnea

2 (18)

Osteoporosis

2 (18)

Other health condition(s)^c

10 (91)

None

0